| Name | Title | Contact Details |
|---|
MMI Genomics is a Davis, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects. To combat resistant infections, physicians may increase dosing of antibiotics, or resort to less safe agents, pushing the safety envelope. Thus, healthcare providers and regulatory agencies increasingly face a difficult choice of balancing the risk of infection against unacceptably high adverse event rates from an effective but relatively toxic antibiotic. For example, in July 2016, FDA imposed a new labeling warning on the toxicity of fluoroquinolones, further restricting the use of this essential class, exemplified by anti-pseudomonal agent ciprofloxacin. Anti-MRSA agent linezolid (Zyvox®) is often used beyond its approved 14-day therapy, resulting in several myelosuppression-associated adverse effects listed in the black box warning for this important drug. MicuRx is addressing the critical need for effective but safer therapeutics by designing novel new compounds with reduced toxicity and adverse events while maintaining excellent clinical efficacy.
TruSpine is a medical device company focused on entering the $10.2 billion (US) per annum spinal device market. The Company is developing uniquely disruptive technologies to revolutionise the spinal stabilisation market, commencing with three flagship pioneering, spinal devices. The Cervi-LOK™ (for the cervical and upper thoracic spine), GRASP Laminoplasty (a treatment for decompression of the spinal cord) & Faci-LOK™ (for the lumbar and lower thoracic spine). These unique devices represent a paradigm shift in spinal fixation, by providing exceptional stabilization while not altering the bony anatomy such as screws, staples or other devices which currently dominate the spinal market. The TruSpine philosophy and mantra is one of preserving nature`s design, and as such, the devices have been designed to be safer, faster and easier to implant. The potential cost savings to patients, insurers and surgeons can be significant. The technology is minimally intrusive, minimally invasive and reversable. The first product to market will be Cervi-LOK™, and will be the first posterior cervical stabilisation device in the world which fully preserves the boney anatomy of the spine. TruSpine has a phased product development strategy, and is planning to commence initial product marketing between late 2020 to early 2021. The overall aim is to establish the TruSpine products as the go-to solutions for the spinal stabilisation market. In addition to the three flagship platform products currently under development, the company also has a pipeline of additional and complementary spinal products.
Selexys Pharmaceuticals is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SomaGenics is a Santa Cruz, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.